Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Arix Bioscience plc    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Arix Bioscience Plc : - Notice of Results

share with twitter share with LinkedIn share with facebook
08/13/2020 | 02:09am EDT

Arix Bioscience plc

Notice of Interim Results

LONDON, 13 August 2020: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its interim results for the six months ended 30 June 2020, on Tuesday 8 September 2020.

Arix will publish a pre-recorded presentation on the same day, at 7.00am BST, followed by a Q&A session accessible via conference call or webcast at 12.30pm BST. The webcast of the presentation will be available on the Company's investor relations website at https://arixbioscience.com/investor-relations/results-centre.

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0) 20 7290 1072
charlotte@arixbioscience.com

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
T: +44 (0) 20 3950 9144
optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


© PRNewswire 2020
share with twitter share with LinkedIn share with facebook
All news about ARIX BIOSCIENCE PLC
09/07ARIX BIOSCIENCE : VelosBio Announces FDA Fast Track and Orphan Drug Designations..
PU
08/13ARIX BIOSCIENCE PLC : - Notice of Results
PR
08/10ARIX BIOSCIENCE PLC : - LogicBio announces IND clearance for LB-001
PR
08/05PHARMAXIS : US$7 Million of US Bronchitol Launch Milestone Payment Brought Forwa..
PU
07/20ARIX BIOSCIENCE PLC : - Amplyx announces positive Phase 2 data
PR
07/10ARIX BIOSCIENCE : Atox Bio Announces a Positive Effect of Reltecimod on Resoluti..
PU
07/10ARIX BIOSCIENCE PLC : - Atox Bio plans NDA submission for Q3 2020
PR
07/08ARIX BIOSCIENCE PLC : - VelosBio completes $137 million Series B financing
PR
07/01ARIX BIOSCIENCE PLC : - Director/PDMR Shareholding, Issue of Ordinary Shares
PR
06/12ARIX BIOSCIENCE PLC : - Aura presents updated AU-011 clinical data at ARVO 2020
PR
More news